Compare CRAI & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRAI | TBPH |
|---|---|---|
| Founded | 1965 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 898.0M | 824.9M |
| IPO Year | 1998 | 2013 |
| Metric | CRAI | TBPH |
|---|---|---|
| Price | $147.54 | $16.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $245.00 | $18.40 |
| AVG Volume (30 Days) | 115.2K | ★ 326.3K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | 20.77 | ★ 279.13 |
| EPS | ★ 8.14 | N/A |
| Revenue | ★ $751,583,000.00 | $15,386,000.00 |
| Revenue This Year | $7.82 | $8.46 |
| Revenue Next Year | $5.14 | N/A |
| P/E Ratio | $18.10 | ★ N/A |
| Revenue Growth | ★ 9.33 | N/A |
| 52 Week Low | $132.17 | $10.56 |
| 52 Week High | $227.29 | $21.03 |
| Indicator | CRAI | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 57.26 |
| Support Level | $142.53 | $16.07 |
| Resistance Level | $166.99 | $17.21 |
| Average True Range (ATR) | 6.78 | 0.32 |
| MACD | 0.66 | 0.07 |
| Stochastic Oscillator | 60.59 | 94.57 |
CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.